MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04454nam a22006497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150318s20142014 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0002-8703 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
25262265 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. |
| 251 ## - Source |
|---|
| Source |
American Heart Journal. 168(4):545-51, 2014 Oct. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Am Heart J. 168(4):545-51, 2014 Oct. |
| 253 ## - Journal Name |
|---|
| Journal name |
American heart journal |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2015-03-18 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: High on-treatment platelet reactivity (HTPR) has been shown to be associated with adverse cardiac events in patients undergoing percutaneous coronary intervention, but the effect of baseline hematologic parameters upon platelet reactivity remains controversial. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSION: Baseline hematocrit has a differential influence on results of the ex vivo platelet functional assays. Lower baseline hematocrit was independently associated with HTPR by VN but not LTA. This may affect the interpretation of platelet function testing in patients with significant anemia.Copyright � 2014 Mosby, Inc. All rights reserved. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: We tested clopidogrel on-treatment platelet reactivity in 466 consecutive patients using VerifyNow P2Y12 (VN) and light transmission aggregometry (LTA) with adenosine diphosphate (ADP) 5 and 20 muM assays 6 to 24 hours after percutaneous coronary intervention. Patients were categorized into 4 groups according to baseline hematocrit. One-year major adverse cardiac events, including death, nonfatal myocardial infarction, and definite stent thrombosis, were collected. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
OBJECTIVE: The present study aims to evaluate the impact of hematocrit on 2 different assay methods used to assess on-treatment platelet reactivity to clopidogrel. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Lower hematocrit was associated with higher P2Y12 reaction unit (PRU) and a higher rate of HTPR (P < .001) as measured by VN assay. No differences were seen among the 4 groups in platelet reactivity measured by LTA using ADP 5 muM (P = .23) and ADP 20 muM (P = .21). In a multivariable logistic regression model, baseline hematocrit was independently associated with PRU >208 (odds ratio [OR] 0.92, 95% CI 0.86-0.97, P = .005) but had no correlation with LTA ADP 5 muM >46% (OR 1.0, 95% CI 0.95-1.06, P = .88) or LTA ADP 20 muM >59% (OR 1.03, 95% CI 0.97-1.09, P = .39). In a logistic regression model, the addition of VN assay results, hematocrit, and interaction between the hematocrit and assay results had shown a significant influence on the area under curve for prediction of 1-year major adverse cardiac events compared with baseline clinical variables only for PRU (0.63 vs 0.76, P = .006) but not with LTA (0.64 vs 0.74, P = .13). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Blood Platelets/de [Drug Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hematocrit/mt [Methods] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Myocardial Infarction/bl [Blood] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Percutaneous Coronary Intervention |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Platelet Aggregation/de [Drug Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Stents |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Ticlopidine/aa [Analogs & Derivatives] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Elective Surgical Procedures/mt [Methods] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Follow-Up Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Myocardial Infarction/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Myocardial Infarction/su [Surgery] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Prospective Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Purinergic P2Y Receptor Antagonists/pd [Pharmacology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Reproducibility of Results |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Ticlopidine/pd [Pharmacology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Chen, Fang |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Lhermusier, Thibault |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Loh, Joshua P |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Magalhaes, Marco A |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Minha, Sa'ar |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Pendyala, Lakshmana K |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Pichard, Augusto D |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Satler, Lowell F |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Torguson, Rebecca |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Waksman, Ron |
| 790 ## - Authors |
|---|
| All authors |
Chen F, Lhermusier T, Loh JP, Magalhaes MA, Minha S, Pendyala LK, Pichard AD, Satler LF, Torguson R, Waksman R |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="http://dx.doi.org/10.1016/j.ahj.2014.06.029">http://dx.doi.org/10.1016/j.ahj.2014.06.029</a> |
| Public note |
http://dx.doi.org/10.1016/j.ahj.2014.06.029 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Journal article |
